Row
R
RGNXAI Stock Diagnostic Report
REGENXBIO sinks as FDA puts RGX-121 gene therapy on clinical hold
REGENXBIO's stock price has declined following the FDA's clinical hold on the RGX-121 gene therapy.
View Source Article ↗AI CATALYST SCORE45 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time